Harmful and Potentially Harmful Constituents in the Filler and Smoke of Tobacco-Containing Tobacco Products

Harmful and Potentially Harmful Constituents in E-Liquids and Aerosols from Electronic Nicotine Delivery Systems (ENDS)

In 2012, the U.S. Food & Drug Administration (FDA) published an established list of 93 harmful and potentially harmful constituents (HPHCs) targeting four tobacco product types (cigarettes, cigarette tobacco, roll-your-own tobacco, smokeless tobacco). In 2016, the FDA finalized the deeming rule to regulate electronic nicotine delivery systems (ENDS). However, knowledge gaps exist regarding whether certain HPHCs are present in ENDS e-liquids and aerosols. We identified and addressed these gaps by conducting literature searches and then experimentally quantifying HPHCs in the e-liquid and aerosol of 37 ENDS brands based on gaps in the literature. The literature searches identified 66 e-liquid HPHCs and 68 aerosol HPHCs that have limited to no information regarding the quantifiability of these constituents. A contracted ISO 17025 accredited laboratory performed the HPHC quantifications. The availability of validated analytical methods in the contracted laboratory determined the HPHCs included in the study scope (63/66 for e-liquids, 64/68 for aerosols). Combining the results from the quantifications and literature searches, 36 (39%) and 34 (37%) HPHCs were found quantifiable (≥limit of quantification [LOQ]) in ENDS e-liquids and aerosols, respectively, with 25 HPHCs being quantifiable in both matrices. Quantifiability results imply potential HPHC transfers between matrices, leaching from components, or formations from aerosol generation. The study results can inform the scientific basis for manufacturers and regulators regarding regulatory requirements for HPHC reporting. The HPHC quantities can also inform evaluations of the public health impact of ENDS and public communications regarding ENDS health risks.

Tracking the Variations in Trace and Heavy Elements in Smoking Products Marketed in Oman and Egypt: Risk Assessment After Implementation of Constraining Protocols

Tobacco smoking is becoming one of the major worldwide concerns regarding environmental pollution as well as health threats. In 2005, the World Health Organization (WHO) released the Framework Convention On Tobacco Control (FCTC), which outlined protocols for controlling tobacco products. Oman was one of the leading countries to follow these protocols; however, Egypt has only followed these protocols recently in 2020. One of the main challenges in tobacco product control is the variation in their trace element's types and amounts from country to country owing to differences in agriculture techniques and used chemical additives. Smoking releases different toxic metal ions found in them into the air, and hence, analyzing trace amounts of metals in tobacco smoking products is becoming more critical. The proposed research aims to evaluate the current levels of 11 heavy metals (namely, As, Pb, Cd, Co, Cr, Be, Ba, Mn, Ni, Fe, and Hg) in 22 tobacco products available in Egypt and Oman using inductively coupled plasma optical emission spectroscopy and a direct mercury analyzer. Although some elements such as Be, Co, and Cd were absent, the positive detection of As and Pb and the levels of Ba, Cr, and Ni are still alarming, especially for heavy smokers. The obtained results were then statistically related to previously published data in 2017 to explore the effectiveness of implementing the FCTC protocols within the Egyptian market. The outcomes suggested a positive impact of FCTC protocol implementation in Egypt, besides the lower levels of elemental content for Omani products compared to the Egyptian market.

Photocatalytic removal of benzo[a]pyrene and antibacterial efficacy of Graphitic Carbon Nitride-silver-nickel (g-C3N4-Ag-Ni) mediated nanocomposites

A few PAHs (polycyclic aromatic hydrocarbons) which are known to be pervasive and are of high priority are found to be detrimental pollutants having high potential in the destruction of the network. Hence, photocatalytic disintegration of these PAHs, namely benzo [a]pyrene, found in water is explored. A novel nanocomposite of Ag-Ni on g-C3N4 was fabricated. The prepared nanocomposites were characterized by techniques like UV, XRD, SEM-EDAX, FTIR, and DLS to understand their nature. The activity of the same as a catalyst in the deterioration of the benzopyrene molecule in water was investigated under different conditions including change in the concentration of the PAH, dosage of the catalyst prepared, pH of the reaction mixture, and by changing the source of irradiation. In addition, antibacterial analysis of the prepared nanocomposite material was conducted to determine whether it could be applied to environmental cleanup strategies of high quality.

Association of serum individual and mixed aldehydes with depressive symptoms in the general population: A machine learning study

BACKGROUND

Humans have many opportunities to be exposed to aldehydes which have potential mechanisms for causing depression. We aimed to explore the relationships between serum individual and mixed aldehydes with depressive symptoms in general population.

METHODS

The data was extracted from the National Health and Nutrition Examination Survey 2013-2014. Depressive symptoms were assessed by Patient Health Questionnaire-9. Weighted binomial logistic regression and Bayesian kernel machine regression (BKMR) model were used to explore the association of six individual aldehyde and mixed aldehydes with depressive symptoms, respectively. Sex stratification analysis and sensitivity analysis were conducted.

RESULTS

A total of 701 participants were included. We found a positive association between the highest (Q4) versus lowest quartile (Q1) of butyraldehyde with depressive symptoms (OR: 2.86, 95 % CI: 1.22-6.68), and a negative association between the Q3 versus Q1 of benzaldehyde (0.21, 0.07-0.60) and isopentanaldehyde (0.28, 0.08-0.90) with depressive symptoms in multivariate-adjusted model. The mixed aldehydes were positively associated with depressive symptoms using BKMR model, and butyraldehyde and heptanaldehyde were the dominant aldehydes. Several aldehydes, such as butyraldehyde and benzaldehyde, interacted with each other in their effects on depressive symptoms. The results of gender stratification analysis showed that butyraldehyde was the major contributor to the total effect of aldehydes on depressive symptoms in males, while heptanaldehyde was the dominant aldehyde in females.

LIMITATIONS

Causality cannot be inferred in this cross-sectional study.

CONCLUSIONS

Our study indicated that mixed aldehydes can increase the risk of depressive symptoms, of which butyraldehyde and heptanaldehyde were the major contributing aldehydes.

Biomarkers of Electronic Nicotine Delivery Systems (ENDS) Use

This perspective summarizes available evidence on biomarkers of exposure in electronic nicotine delivery system (ENDS) users to aid the overall assessment of the health consequences of using ENDS. Identification of novel biomarkers of exposure specific to ENDS use remains challenging because chemicals emitted from ENDS devices have many familiar sources. The biomarker levels of many tobacco-related toxicants measured in biological samples collected from ENDS users did not differ significantly from non-users, except for nicotine metabolites and a small number of biomarkers of exposure to volatile organic compounds and tobacco-specific tobacco nitrosamines. Several studies have shown that while exposed to nicotine, long-term exclusive ENDS users showed significantly lower levels of toxicant biomarkers than cigarette smokers. Studies have also shown that concurrent users of ENDS and combustible cigarettes ('dual users') are not reducing overall exposure to harmful toxicants compared to exclusive cigarette smokers. Because of an absence of validated ENDS-specific biomarkers, we recommend combining several biomarkers to differentiate tobacco product user groups in population-based studies and monitor ENDS compliance in randomized controlled trials. Using a panel of biomarkers would provide a better understanding of health effects related to ENDS use.